China approves subcutaneous auto-injector for Alzheimer’s drug Leqembi

This approval marks a meaningful shift in Alzheimer's care accessibility in China, moving a complex therapy from clinical settings to patient homes. It signals regulatory openness to patient-centric delivery models for neurodegenerative diseases, which could influence how other markets evaluate similar devices. The move may also pressure healthcare systems to develop infrastructure for at-home administration and monitoring. Whether other Asian regulators follow China's lead—and how Eisai manages real-world safety outside clinical supervision—are the key dynamics to track.